Article

LASIK Xtra gets CE approval

Avedro Inc.’s proprietary LASIK Xtra procedure has received CE mark approval. LASIK Xtra is a 2-minute corneal crosslinking procedure used in conjunction with standard LASIK to restore the biomechanical integrity and strength to the cornea after a LASIK procedure.

Waltham, MA-Avedro Inc.’s proprietary LASIK Xtra procedure has received CE mark approval. LASIK Xtra is a 2-minute corneal crosslinking procedure used in conjunction with standard LASIK to restore the biomechanical integrity and strength to the cornea after a LASIK procedure.

LASIK Xtra has been successfully used in thousands of LASIK surgeries outside the United States.

“Crosslinking within a LASIK procedure using LASIK Xtra is simple, fast and safe,” said A. John Kanellopoulos, MD, a member of Avedro’s medical advisory board. “In studies we’ll be reporting at ASCRS in April, we’ve found that after almost 2 years of follow-up, [patients with hyperopia] appear to have a completely different clinical course if we employ prophylactic crosslinking in their LASIK procedures. Hyperopic LASIK typically regresses more than myopic LASIK.”

LASIK Xtra combines riboflavin ophthalmic solution (VibeX) with its UVA irradiation system (KXL System) to achieve accelerated corneal crosslinking during a LASIK procedure.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.